IPI-145 shows promise in CLL patients.

Article Details

Citation
Copy to clipboard

Authors unspecified

IPI-145 shows promise in CLL patients.

Cancer Discov. 2014 Feb;4(2):136. doi: 10.1158/2159-8290.CD-NB2013-177. Epub 2013 Dec 12.

PubMed ID
24501284 [ View in PubMed
]
Abstract

Results from a phase I study of Infinity Pharmaceuticals' IPI-145, which inhibits both delta and gamma isoforms of phosphoinositide3-kinase, suggest the drug is safe and effective in patients with advanced chronic lymphocytic leukemia.

DrugBank Data that Cites this Article

Drugs